APA (7th ed.) Citation

Hehlmann, R., Lauseker, M., Jung-Munkwitz, S., Leitner, A., Müller, M. C., Pletsch, N., . . . Saußele, S. (2011). Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. Journal of clinical oncology. [Englische Ausgabe], 29(12), .

Chicago Style (17th ed.) Citation

Hehlmann, Rüdiger, et al. "Tolerability-adapted Imatinib 800 Mg/d Versus 400 Mg/d Versus 400 Mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia." Journal of Clinical Oncology. [Englische Ausgabe] 29, no. 12 (2011).

MLA (9th ed.) Citation

Hehlmann, Rüdiger, et al. "Tolerability-adapted Imatinib 800 Mg/d Versus 400 Mg/d Versus 400 Mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia." Journal of Clinical Oncology. [Englische Ausgabe], vol. 29, no. 12, 2011.